Literature DB >> 23689360

Impairment in natural killer cells editing of immature dendritic cells by infection with a virulent Trypanosoma cruzi population.

Estela I Batalla1, Agustina M Pino Martínez, Carolina V Poncini, Tomás Duffy, Alejandro G Schijman, Stella M González Cappa, Catalina D Alba Soto.   

Abstract

Early interactions between natural killer (NK) and dendritic cells (DC) shape the immune response at the frontier of innate and adaptive immunity. Activated NK cells participate in maturation or deletion of DCs that remain immature. We previously demonstrated that infection with a high virulence (HV) population of the protozoan parasite Trypanosoma cruzi downmodulates DC maturation and T-cell activation capacity. Here, we evaluated the role of NK cells in regulating the maturation level of DCs. Shortly after infection with HV T. cruzi, DCs in poor maturation status begin to accumulate in mouse spleen. Although infection induces NK cell cytotoxicity and cytokine production, NK cells from mice infected with HV T. cruzi exhibit reduced ability to lyse and fail to induce maturation of bone marrow-derived immature DCs (iDCs). NK-mediated lysis of iDCs is restored by in vitro blockade of the IL-10 receptor during NK-DC interaction or when NK cells are obtained from T. cruzi-infected IL-10 knockout mice. These results suggest that infection with a virulent T. cruzi strain alters NK cell-mediated regulation of the adaptive immune response induced by DCs. This regulatory circuit where IL-10 appears to participate might lead to parasite persistence but can also limit the induction of a vigorous tissue-damaging T-cell response.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23689360      PMCID: PMC6741459          DOI: 10.1159/000350242

Source DB:  PubMed          Journal:  J Innate Immun        ISSN: 1662-811X            Impact factor:   7.349


  45 in total

1.  Transmission of Toxoplasma gondii from infected dendritic cells to natural killer cells.

Authors:  Catrine M Persson; Henrik Lambert; Polya P Vutova; Isabel Dellacasa-Lindberg; Joanna Nederby; Hideo Yagita; Hans-Gustaf Ljunggren; Alf Grandien; Antonio Barragan; Benedict J Chambers
Journal:  Infect Immun       Date:  2009-01-12       Impact factor: 3.441

2.  Targeting of human dendritic cells by autologous NK cells.

Authors:  J L Wilson; L C Heffler; J Charo; A Scheynius; M T Bejarano; H G Ljunggren
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

3.  [Isolation of a strain of Trypanosoma cruzi from a patient with chronic Chagas cardiomyopathy and its biological characterization].

Authors:  S M González Cappa; P Chiale; G E del Prado; A M Katzin; G W de Martini; E D de Isola; L Abramo Orrego; E L Segura
Journal:  Medicina (B Aires)       Date:  1980       Impact factor: 0.653

4.  [Isolation of a Trypanosoma cruzi strain of predominantly slender form in Argentina].

Authors:  S M González Cappa; A T Bijovsky; H Freilij; L Muller; A M Katzin
Journal:  Medicina (B Aires)       Date:  1981       Impact factor: 0.653

5.  Dendritic cells devoid of IL-10 induce protective immunity against the protozoan parasite Trypanosoma cruzi.

Authors:  Catalina D Alba Soto; Maria Elisa Solana; Carolina V Poncini; Agustina M Pino-Martinez; Valeria Tekiel; Stella Maris González-Cappa
Journal:  Vaccine       Date:  2010-09-16       Impact factor: 3.641

6.  A flow-cytometric NK-cytotoxicity assay adapted for use in rat repeated dose toxicity studies.

Authors:  Maritha Marcusson-Ståhl; Karin Cederbrant
Journal:  Toxicology       Date:  2003-12-01       Impact factor: 4.221

7.  PPARγ ligand treatment inhibits cardiac inflammatory mediators induced by infection with different lethality strains of Trypanosoma cruzi.

Authors:  Federico Penas; Gerardo A Mirkin; Eugenia Hovsepian; Agata Cevey; Roberto Caccuri; María Elena Sales; Nora B Goren
Journal:  Biochim Biophys Acta       Date:  2012-08-16

8.  Dendritic cell editing by activated natural killer cells results in a more protective cancer-specific immune response.

Authors:  Barbara Morandi; Lorenzo Mortara; Laura Chiossone; Roberto S Accolla; Maria Cristina Mingari; Lorenzo Moretta; Alessandro Moretta; Guido Ferlazzo
Journal:  PLoS One       Date:  2012-06-19       Impact factor: 3.240

9.  Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells.

Authors:  Guido Ferlazzo; Ming L Tsang; Lorenzo Moretta; Giovanni Melioli; Ralph M Steinman; Christian Münz
Journal:  J Exp Med       Date:  2002-02-04       Impact factor: 14.307

10.  Accurate real-time PCR strategy for monitoring bloodstream parasitic loads in chagas disease patients.

Authors:  Tomas Duffy; Margarita Bisio; Jaime Altcheh; Juan Miguel Burgos; Mirta Diez; Mariano Jorge Levin; Roberto Rene Favaloro; Hector Freilij; Alejandro Gabriel Schijman
Journal:  PLoS Negl Trop Dis       Date:  2009-04-21
View more
  4 in total

1.  Interleukin 10 Polymorphisms as Risk Factors for Progression to Chagas Disease Cardiomyopathy: A Case-Control Study and Meta-Analysis.

Authors:  Alicia Grijalva; Lucia Gallo Vaulet; Roberto Nicolas Agüero; Analia Toledano; Marikena Guadalupe Risso; Juan Quarroz Braghini; David Sosa; Paula Ruybal; Silvia Repetto; Catalina Dirney Alba Soto
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

Review 2.  Dendritic Cells: A Double-Edged Sword in Immune Responses during Chagas Disease.

Authors:  Natalia Gil-Jaramillo; Flávia N Motta; Cecília B F Favali; Izabela M D Bastos; Jaime M Santana
Journal:  Front Microbiol       Date:  2016-07-14       Impact factor: 5.640

Review 3.  The Unsolved Jigsaw Puzzle of the Immune Response in Chagas Disease.

Authors:  Gonzalo R Acevedo; Magalí C Girard; Karina A Gómez
Journal:  Front Immunol       Date:  2018-08-24       Impact factor: 7.561

4.  Comprehensive analysis of miRNA-mRNA regulatory network and potential drugs in chronic chagasic cardiomyopathy across human and mouse.

Authors:  Jiahe Wu; Jianlei Cao; Xiaorong Hu; Yongzhen Fan; Chenze Li
Journal:  BMC Med Genomics       Date:  2021-11-29       Impact factor: 3.063

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.